Takara Bio Inc.
- Country
- 🇸🇪Sweden
- Ownership
- Private
- Established
- 1984-01-01
- Employees
- 101
- Market Cap
- -
- Website
- https://www.takarabio.com
Clinical Trials
21
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (20 trials with phase data)• Click on a phase to view related trials
Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.
- Conditions
- Pancreatic Cancer Stage IIIPancreatic Cancer Stage IV
- Interventions
- First Posted Date
- 2017-08-17
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Takara Bio Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03252808
- Locations
- 🇯🇵
Clinical Site, Osaka, Japan
Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Takara Bio Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03250325
- Locations
- 🇯🇵
Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan
🇯🇵Mie University Hospital, Tsu, Mie, Japan
🇯🇵National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Lymphoblastic Leukemia, Acute Adult
- Interventions
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Takara Bio Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT03155191
- Locations
- 🇯🇵
University Of Fukui Hospital, Yoshida, Fukui, Japan
🇯🇵Kyushu University Hospital, Higashi-ku, Fukuoka, Japan
🇯🇵Hokkaido University Hospital, Sapporo-shi, Hokkaido, Japan
A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma
- Conditions
- Melanoma Stage IVMelanoma Stage III
- Interventions
- Biological: TBI-1401(HF10)
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Takara Bio Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT03153085
- Locations
- 🇯🇵
Clinical Site, Ōsaka, Japan
A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions
- Conditions
- Solid Tumor
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Takara Bio Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02428036
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
- Prev
- 1
- 2
- Next
News
Advancements in Acute Lymphocytic Leukemia (ALL) Treatment Landscape
The FDA approved obecabtagene autoleucel (Aucatzyl) for adults with relapsed or refractory B-cell precursor ALL, marking a significant advancement in CAR T-cell therapy.